Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

Swiss drugmaker Novartis has terminated a mid-stage study testing its drug ​Fabhalta in patients with a ‌serious kidney condition, citing "strategic considerations", according to a federal clinical tr...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。